Treatment Advances

Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Myeloma Treatments that Target the Microenvironment

November 14, 2024

Learn about the microenvironment and how certain treatments target myeloma cells' interaction with the cells around them.

New Treatment Coming for High-Risk Smoldering Myeloma?

November 12, 2024

Johnson & Johnson seeks FDA and EMA approval for Darzalex Faspro in high-risk smoldering myeloma, aiming to change the treatment paradigms.

Azer-cel, a New CAR T-Cell Therapy for DLBCL

November 08, 2024

Explore an innovative trial using Azer-cel, an allogeneic CAR T-cell therapy, for relapsed DLBCL patients, focusing on safety and effectiveness.

How Myeloma Induction Therapy Is Evolving: Vital Insights for Newly Diagnosed Patients

November 07, 2024

Learn what newly diagnosed multiple myeloma patients need to know about how induction (starting) therapy is evolving in the myeloma treatment landscape.

The First Medication To Treat CD19+ Acute Lymphoblastic Leukemia

November 01, 2024

Learn about how VNX-101 can help ALL patients that are CD19 positive.

A New CAR T-Cell Therapy Treatment for ALL

November 01, 2024

Learn how a new treatment option for acute lymphocytic leukemia, a CAR T therapy called obe-cel, can be an effective treatment.

Understanding Your Treatment Options After Being Diagnosed with Advanced-Stage Follicular Lymphoma

October 29, 2024

If you are a person with advanced-stage follicular lymphoma who is starting their first treatment, learn how certain therapy options compare.

AML: Donor Age, Not Just a Number

October 24, 2024

Discover key insights into AML donor selection, HLA mismatch, and the role of donor age in improving transplant outcomes and reducing complications.

Venetoclax + Decitabine Improve Senior AML Patients’ Chances of Receiving a Transplant

October 22, 2024

Learn how venetoclax and decitabine helped a higher percentage of senior AML patients achieve a complete reduction in AML signs/symptoms and reach transplant.